Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model.

• Material Type: 博士論文
• Title: Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model.
• Author/Editor: Aihara, Yosuke; Yoshiji, Hitoshi; Noguchi, Ryuichi; Kaji, Kosuke; Namisaki, Tadashi; Shirai, Yusaku; Douhara, Akitoshi; Moriya, Kei; Kawaratani, Hideto; Fukui, Hiroshi
• Author Heading: Aihara, Yosuke; Yoshiji, Hitoshi; Noguchi, Ryuichi; Kaji, Kosuke; Namisaki, Tadashi; Shirai, Yusaku; Douhara, Akitoshi; Moriya, Kei; Kawaratani, Hideto; Fukui, Hiroshi
• Publication, Distribution, etc.: Wiley / The Japan Society of Hepatology
• Publication Date: 2013-11
• Publication Date (W3CDTF): 2013-11
• Alternative Title: 直接的レニン阻害薬であるアリスキレンはラットモデルにおいて非アルコール性脂肪肝炎の進行を抑制する
• Periodical title: Hepatology research
• No. or year of volume/issue: 43 11
• Volume: 43
• Issue: 11
• Pages: 1241-1250
• ISSN (Periodical Title): ISSN : 1386-6346
• Degree grantor/type: 奈良県立医科大学
• Date Granted: 2014-03-17
• Dissertation Number: 甲第612号
• Degree Type: 博士（医学）
• Text Language Code: eng
• Subject Heading: angiotensin-II; hepatocarcinogenesis; liver fibrosis; non-alcoholic; steatohepatitis; renin
• Target Audience: 一般
• Note (General): type:Thesis; AIM: Renin is a rate-limiting enzyme of the renin-angiotensin system (RAS), and several reports have shown that renin plays an important role in several pathological processes. Although RAS is known to play a pivotal role in the progression of non-alcoholic steatohepatitis (NASH), the role of renin is still obscure. The aim of the current study was to examine the effect of the clinically used direct renin inhibitor (DRI), aliskiren, on the progression of NASH in a rat model. METHODS: The effects of DRI on the choline-deficient L-amino acid-defined (CDAA) diet-induced rat NASH model was examined in conjunction with the activated hepatic stellate cells (Ac-HSC) and neovascularization, both of which are known to play important roles in liver fibrosis development and hepatocarcinogenesis, respectively. RESULTS: DRI exerted a marked inhibitory effect against liver fibrosis development and glutathione-S-transferase placental form (GST-P) positive preneoplastic lesions along with suppression of the Ac-HSC and neovascularization in a dose-dependent manner. DRI also inhibited the hepatic expressions of transforming growth factor-beta 1 (TGF-beta 1), angiotensin-II (AT-II) and vascular endothelial growth factor (VEGF). These results indicated that renin played a pivotal role in the liver fibrosis development and hepatocarcinogenesis of NASH. CONCLUSION: Because DRI is already widely used in the clinical practice with safety, this drug may represent a potential new strategy against the progression of NASH in the future.; 博士（医学）・甲612号・平成26年3月17日; identifier:Hepatology research Vol.43 No.11 p.1241-1250; identifier:13866346; identifier:http://ginmu.naramed-u.ac.jp/dspace/handle/10564/2697; identifier:Hepatology research, 43(11): 1241-1250
• Source: fulltext; http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/2697/1/01%e6%9c%ac%e6%96%87%e3%81%ae%e8%a6%81%e6%97%a8.pdf; http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/2697/2/02%e5%af%a9%e6%9f%bb%e8%a6%81%e6%97%a8.pdf; http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/2697/6/03%e6%9c%ac%e6%96%87.pdf
• Access Restrictions: インターネット公開
• Related Material (DOI): 10.1111/hepr.12081
• Periodical Title (NCID): AA11140867; https://ci.nii.ac.jp/ncid/AA11140867
• Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• Original Data Provider (Database): 奈良県立医科大学 : 奈良県立医科大学機関リポジトリ GINMU